arrow
J

Junlin Yi

Chinese Academy of Medical Sciences and Peking Union Medical College
H指数:26
被引数:3,276

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical characteristics, management, and outcomes of lacrimal gland adenoid cystic carcinoma: a single-center series with contextual comparison to SEER data

泪腺腺样囊性癌的临床特征、治疗及预后:一项与SEER数据比较的单中心病例系列研究

2026-09-180
OA
Simultaneous Integrated Dose Reduction Radiotherapy Versus Conventional Fractionated Radiotherapy With Chemotherapy for Limited-Stage Small-Cell Lung Cancer in the Modern Treatment Era: a Phase III, Randomized Clinical Trial (SDR-RT trial)

同步整合剂量降低放射疗法与常规分割放射疗法联合化疗治疗现代治疗时代局限期小细胞肺癌的随机III期临床试验(SDR-RT试验)

2025-10-140
PRE
Impact of consolidation immunotherapy after definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a real-world multicenter study

局部晚期食管鳞状细胞癌在根治性放化疗后巩固性免疫治疗的疗效:一项真实世界多中心研究

2025-10-130
PRE
Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas

鼻咽癌放射治疗中的大体肿瘤靶区勾画:CSTRO、CACA、CSCO、HNCIG、ESTRO和ASTRO指南及勾画图谱

2025-09-010
PRE
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas

鼻咽癌放疗中颈部靶区的勾画:CSTRO、CACA、CSCO、HNCIG、ESTRO和ASTRO指南及勾画图谱

2025-09-010
PRE
Treatment response-adapted risk index model for survival prediction and adjuvant chemotherapy selection in nonmetastatic nasopharyngeal carcinoma

基于治疗反应的生存预测与非转移性鼻咽癌辅助化疗选择的适应性风险指数模型

2025-09-010
OAAI
Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial

替雷利珠单抗联合白蛋白结合型紫杉醇和顺铂作为局部晚期喉咽鳞状细胞癌器官保留的诱导免疫化疗:一项单臂II期试验

2025-07-250
OAAI
International Consensus Guideline on Delineation of the Clinical Target Volumes at Different Dose Levels for Nasopharyngeal Carcinoma (2024 Version)

《鼻咽癌不同剂量水平临床靶区勾画国际共识指南(2024年版)》

2025-05-240
OAAI